1 Continuing Education Information CE (Continuing Education for non-physicians) The CAP designates this educational activity for a maximum of 1 credit of continuing education. Participants should only claim credit commensurate with the extent of their participation in the activity. The American Society for Clinical Pathology (ASCP) Board of Certification (BOC) Certification Maintenance Program (CMP) accepts this activity to meet the continuing education requirements. This activity is approved for continuing education credit in the states of California and Florida. Disclosure Statement The following authors/planners have financial relationships to disclose: None The following authors/planners have no financial relationships to disclose: Horatiu Olteanu MD, PhD, FCAP Kyle T. Bradley, MD, MS, FCAP Stephanie A. D3dx9_43.dll license key. Salansky, MEd, MS, MT(ASCP) The following In-Kind Support has been received for this activity: None The following Commercial Support has been received for this activity: None All authors/planners of a CAP educational activity must disclose to the program audience any financial interest or relationship with the manufacturer(s) of any commercial product(s) that may be discussed in the educational activity or with the manufacturer of a product that is directly competitive with a product discussed in the presentation. Relevant financial relationships are considered to be any financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The College of American Pathologists does not view the existence of these interests or uses as implying bias or decreasing the value to participants. The CAP feels that this disclosure is important for the participants to form their own judgment about each presentation. All College educational activities hold to the highest standards of educational quality and are dedicated to promoting improvement in health care quality and not a specific proprietary business interest of a commercial interest. All recommendations and/or planning criteria involving clinical medicine are based on evidence that is accepted within the profession of medicine as adequate justification for this indication and contraindication in the care of patients. Learning Objectives Upon completing the reading and answering the learning assessment questions, you should be able to: 1. Identify the major clinical uses of dapsone in immunocompromised patients. List the adverse effects associated with dapsone prophylaxis. Review the morphologic and laboratory diagnosis of dapsone-induced oxidant hemolysis. List the differential diagnostic considerations in oxidant hemolysis and the characteristics that distinguish them. Understand the genetic, clinical, and laboratory manifestations of G6PD deficiency. All material is 2016 College of American Pathologists, all rights reserved 2 Case Presentation: This peripheral blood smear is from a 52-year-old woman with immune deficiency who is currently on dapsone prophylaxis. Dum dee dum song download. A color atlas of hematology Eric F. Northfield, IL, College of American Pathologists. PDF (132 KB) Email Article Add to My Reading List. Laboratory data include WBC = 9.4 x 10 9 /L; RBC = 2.98 x /L; HGB = 9.1 g/dl; HCT = 31.5%; MCV = 90 fl; RDW = 20; PLT = 187 x 10 9 /L. INTRODUCTION This is a representative case of dapsone-associated oxidant hemolysis. The patient has a history of immune deficiency, which often times requires prophylactic administration of dapsone for a variety of opportunistic infections. The complete blood count (CBC) shows a moderate normochromic, normocytic anemia with moderate anisopoikilocytosis and normal platelet and white blood cell (WBC) counts. A keygen is made available through crack groups free to download. When writing a keygen, the author will identify the algorithm used in creating a valid cd key. Scanmaster-elm v2.1 keygen. The peripheral blood smear shows numerous bite cells, occasional spherocytes, and reticulocytes. The following discussion addresses the clinical utility of dapsone use in immunocompromised patients, the adverse effects associated with dapsone prophylaxis, the morphologic and laboratory diagnosis of dapsone-induced oxidant hemolysis, and an overview of glucose-6- phosphate dehydrogenase (G6PD) deficiency. Dapsone (4-4 -diaminodiphenylsulfone) is a synthetic sulfa drug with multiple antimicrobial activities. It was initially shown to have bactericidal and bacteriostatic activity against Mycobacterium leprae. In addition to being active in the treatment of patients with leprosy (documented in the 1940s), dapsone is also active in high concentrations against several other species of mycobacteria, including Mycobacterium tuberculosis and Mycobacterium avium complex. In combination with other drugs, such as pyrimethamine, dapsone has been used as chemoprophylaxis for malaria due to chloroquine-resistant Plasmodium falciparum and Plasmodium vivax. Dapsone, alone or in combination with trimethoprim and pyrimethamine, can effectively prevent and treat Pneumocystis jirovecii pneumonia (PCP), which is a serious and potentially life-threatening infection that can occur in immunocompromised individuals. Some evidence also suggests it has activity against Toxoplasma gondii. USE OF DAPSONE IN PCP PROPHYLAXIS The strong anti-pneumocystis activity of dapsone has been demonstrated in numerous clinical trials. The drug blocks folic acid synthesis of Pneumocystis jirovecii by inhibition of dihydropteroate activity.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2019
Categories |